The 24th Annual General Meeting of the Developing Countries Vaccine Manufacturers' Network (DCVMN), held in Cape Town, South Africa and co-hosted by Biovac, convened over 400 delegates and featured more than 100 distinguished speakers across three days. This gathering served as a vital platform for vaccine manufacturers from developing nations to share insights, challenges, and achievements, underscoring their pivotal role in global vaccine research, development, and distribution to promote vaccine equity. The conference theme centered on partnerships in various forms and their instrumental role in assisting local manufacturers in achieving their and global health objectives. Speakers provided comprehensive reviews of the vaccine industry's current landscape, covering aspects such as development, manufacturing, quality control, technology transfer, and gender-related immunization, with a focus on the perspectives of DCVMs. This paper focuses on these interconnected areas, examining their present status through the perspectives of our member manufacturers and prominent global health organizations.
No takes yet. Share an insight, caveat, or question.
Suri et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: